- Home
- V vs NVS Comparison
V vs NVS Comparison
Compare V & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | V | NVS |
|---|---|---|
| Founded | 1958 | 1895 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 613.8B | 292.0B |
| IPO Year | 2007 | 2001 |
Fundamental Metrics
Financial Performance| Metric | V | NVS |
|---|---|---|
| Price | $408.10 | $150.87 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 40 | 12 |
| Target Price | ★ $422.77 | $154.65 |
| AVG Volume (30 Days) | ★ 5.3M | 1.5M |
| Earning Date | 10-27-2026 | 10-27-2026 |
| Dividend Yield | 0.65% | ★ 1.97% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $21,846,000,000.00 | N/A |
| Revenue This Year | $14.45 | $1.73 |
| Revenue Next Year | $10.97 | $6.39 |
| P/E Ratio | $30.09 | ★ $23.13 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $293.89 | $121.57 |
| 52 Week High | $414.60 | $170.46 |
Technical Indicators
Market Signals| Indicator | V | NVS |
|---|---|---|
| Relative Strength Index (RSI) | 70.16 | 56.65 |
| Support Level | $360.18 | $149.30 |
| Resistance Level | N/A | $155.26 |
| Average True Range (ATR) | 6.62 | 2.26 |
| MACD | 2.83 | 1.29 |
| Stochastic Oscillator | 85.96 | 64.67 |
Price Performance
Historical ComparisonAbout V Visa Inc.
Visa is the largest payment processor in the world. In fiscal 2025, it processed almost $17 trillion in total volume. Visa operates in over 200 countries and processes transactions in over 160 currencies. Its systems are capable of processing over 65,000 transactions per second.
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.